Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Iannone

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
Plos One|January 3, 2018
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyLoreta A Kondili, Giovanni Battista Gaeta, Donatella Ieluzzi, et al.
Viruses|May 25, 2024
Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV)Maria Giovanna Quaranta, Luisa Cavalletto, Francesco Paolo Russo, et al.
Hepatology (Baltimore, Md.)|December 17, 2021
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohortLoreta A Kondili, Monica Monti, Maria Giovanna Quaranta, et al.
United European Gastroenterology Journal|November 30, 2023
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohortLoreta A Kondili, Alberto Zanetto, Maria Giovanna Quaranta, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 15, 2018
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?Loreta A Kondili, Sarah Robbins, Sarah Blach, et al.
Plos One|October 5, 2017
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER networkLoreta A Kondili, Giovanni Battista Gaeta, Maurizia Rossana Brunetto, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
Plos One|January 3, 2018
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyLoreta A Kondili, Giovanni Battista Gaeta, Donatella Ieluzzi, et al.
Viruses|May 25, 2024
Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV)Maria Giovanna Quaranta, Luisa Cavalletto, Francesco Paolo Russo, et al.
Hepatology (Baltimore, Md.)|December 17, 2021
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohortLoreta A Kondili, Monica Monti, Maria Giovanna Quaranta, et al.
United European Gastroenterology Journal|November 30, 2023
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohortLoreta A Kondili, Alberto Zanetto, Maria Giovanna Quaranta, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 15, 2018
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?Loreta A Kondili, Sarah Robbins, Sarah Blach, et al.
Plos One|October 5, 2017
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER networkLoreta A Kondili, Giovanni Battista Gaeta, Maurizia Rossana Brunetto, et al.
Pageof 9